Top Markets
Coin of the day
Solasia Pharma K.K. Solasia Pharma K.K.

Solasia Pharma K.K.

4597
株式のランク #24757
Established in 2006 and headquartered in Tokyo, Japan, Solasia Pharma K.K. is... Established in 2006 and headquartered in Tokyo, Japan, Solasia Pharma K.K. is dedicated to the development and commercialization of oncology treatments throughout Japan and other parts of Asia. The company's marketed products include SP-03 (episil oral liquid), designed for the protection and relief of oral pain and inflammation (mucositis/stomatitis) resulting from cancer chemotherapy and radiation. Additionally, they offer SP-01 (Sancuso), a transdermal patch that delivers granisetron, an anti-emetic, into the bloodstream to manage chemotherapy-induced nausea and vomiting. Solasia Pharma's development pipeline features SP-02 (Darinaparsin), a mitochondrial-targeted agent that has successfully completed Phase III clinical trials for a range of hematologic and solid cancers. Also in Phase III clinical study is SP-05 (Arfolitixorin), which aims to bolster the anti-tumor effectiveness of fluorouracil in various cancers, including pancreatic, breast, stomach, and head and neck cancers. In its pre-clinical stage, SP-04 is being developed to address chemotherapy-induced peripheral neuropathy.
株価
$0.20877985
時価総額
$57.00M
変化(1日)
-11.11%
変化(1年)
-20.59%
JP
取引 Solasia Pharma K.K. (4597)

カテゴリー

Solasia Pharma K.K.(4597)の配当利回りの履歴
Solasia Pharma K.K.(銘柄コード: 4597)の配当利回り(TTM)は2026時点で0です。
過去5年間の平均配当利回り: 0.00%
Solasia Pharma K.K.(4597)の2026から2026までの配当利回りの履歴
各年末時点の配当利回り(TTM)
配当利回り 変化
提供された日付のデータは十分ではありません。
類似企業または競合他社の配当利回り(TTM)